Condition: Bronchiolitis Obliterans Syndrome · Bronchiolitis Obliterans · Lung Diseases · Sponsor: Dana-Farber Cancer Institute
The goal of this research study is to test the efficacy of a novel immunosuppressive agent, belumosudil, in allogeneic hematopoietic stem cell transplant (HSCT) recipients who have been newly diagnosed or have developing (early stage) bronchiolitis obliterans syndrome (BOS). The name of the study drugs involved in this study are: * Belumosudil (an immunotherapy) * Fluticasone (an intranasal corticosteroid) * Azithromycin (an antibiotic) * Montelukast (a leukotriene receptor antagonist) * Prednisone (a corticosteroid)
This description comes directly from the study's public registry record.
Corey Cutler, MD, MPH · 617-632-5946 · CSCUTLER@PARTNERS.ORG
Always discuss trial participation with your own doctor first.
| Stanford University School of Medicine | Stanford, California, United States | Recruiting |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| Boston Children's Hospital | Boston, Massachusetts, United States | Not Yet Recruiting |
| Brigham and Women's Hospital | Boston, Massachusetts, United States | Not Yet Recruiting |
| University of Michigan | Ann Arbor, Michigan, United States | Recruiting |
| Fred Hutchinson Cancer Center | Seattle, Washington, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05922761